HOME >> MEDICINE >> NEWS
Pitt transplant researchers say anti-rejection drug rapamycin may help lupus, some cancers

PITTSBURGH, Jan. 22 Rapamycin, a drug approved for use in kidney transplant patients to prevent organ rejection, could also benefit patients with lupus and other autoimmune diseases as well as patients with blood cancers, such as acute myeloid leukemia, reports a team of researchers from the University of Pittsburgh's Thomas E. Starzl Transplantation Institute and Institute of Clinical Immunology and Transfusion Medicine, Justus-Liebig University in Giessen, Germany.

Their conclusions, outlined in a paper to be published in the journal Blood and currently posted on the journal's Web site (www.bloodjournal.org), were based on two key discoveries about rapamycin's mechanisms.

First, while rapamycin suppresses immune system T cells, as many anti-rejection drugs do, the researchers found that the drug also inhibits the function and activation of dendritic cells, cells that play a much earlier role in the immune response as the first cells to identify foreign intruders. They in turn present these intruders to other immune system cells, including T cells.

Second, and perhaps more surprising to the study's authors, rapamycin disarms the trigger that allows dendritic cells to proliferate. This trigger, a potent, naturally occurring growth factor, also affects the proliferation of blood precursor and stem cells, which if allowed to grow unchecked, result in leukemia and other cancers.

"Rapamycin's effect on dendritic cells impairs immune reactivity at the earliest stages. Because dendritic cells are important for the initiation and regulation of immune response, this effect is very important. Our findings provide novel insight into the pharmacology of this agent and have significant implications for the development of new therapeutic strategies in disease processes in which dendritic cells play a crucial immunopathological role," stated Angus W. Thomson, Ph.D., D.Sc., professor of surgery and immu
'"/>

Contact: Lisa Rossi
412-647-3555
University of Pittsburgh Medical Center
22-Jan-2003


Page: 1 2

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Alcohol relapse adversely affects 10-year liver transplant survival
3. Donor age has no affect on long-term liver transplant survival
4. Age shouldnt be a factor in kidney transplantation
5. Cornea transplants can be improved
6. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
7. Hard choices: Pitt researcher presents findings on when to accept organ transplants
8. Biochemical marker aids prognosis in liver transplant patients
9. Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
10. Age should not be a factor in determining heart transplantation eligibility, researchers say
11. Study explores risks of obesity in children with kidney transplants

Post Your Comments:
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
(Date:4/17/2014)... 2014While 94 per cent of Canadians surveyed said they ... for a specific number of genetic conditions, only 80 ... in screening that would sequence their newborns, genomes.,Most newborns ... their first day or two of life in which ... heels and tested for about five to 54 conditions, ...
(Date:4/16/2014)... Calif. Consider the marvel of the embryo. It begins ... function as they multiply to become the cells of our ... the body. , Now, in a feat of reverse tissue ... genetic coding that allows embryonic cells to proliferate and transform ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
Cached News: